Yiannakou Yan, Etherson Kevin, Close Helen, Kasim Adetayo, Mercer-Jones Mark, Plusa Stefan, Maier Rebecca, Green Susan, Cundall Jeremy, Knowles Charles, Mason James
Departments of Neurogastroenterology.
Department of Colorectal Surgery, North Tees and Hartlepool NHS Foundation Trust, Stockton.
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):653-660. doi: 10.1097/MEG.0000000000001379.
Sacral nerve stimulation (SNS) may provide long-term symptom relief to patients suffering from chronic constipation. Patients are currently selected for SNS using a 2-week peripheral nerve evaluation (PNE) comprising stimulation by temporary leads. However, only 40% of test responders receive long-term benefit from treatment meaning that healthcare costs per successfully treated patient are too high. The primary objective was to assess tined-lead testing to predict benefit from SNS for chronic constipation.
A randomized double-blind sham-controlled cross-over design evaluated enhanced PNE (ePNE) using tined quadripolar electrode leads over 6 weeks. The design differentiated between patients with discriminate and indiscriminate responses to testing. A score improvement of 25% or more was considered to be a positive response within a stimulation period. The primary outcome was the proportion of patients showing a reduction of at least 0.5 in constipation symptom score at 6 months.
A total of 45 patients were randomized, of whom 29 (64.4%) were test-phase responders. Of these, 27 were implanted providing permanent SNS. During ePNE, seven (18%) were discriminate responders, 22 (56%) were indiscriminate responders and 10 (26%) were nonresponders. Six patients were withdrawn during the test phase because of infection or noncompliance. At 6 months, there was no significant difference in primary outcome between discriminate and indiscriminate responders (60 vs. 57%, P=0.76). The study was terminated prematurely because of a persistent infection rate of 10 (22%) during ePNE of which nine (20%) were severe.
ePNE is a poor predictor of treatment response at 6 months. This suggests a strong and persistent placebo response during both SNS PNE and treatment. An extended 6-week PNE poses a high risk of infection.
骶神经刺激(SNS)可为慢性便秘患者提供长期症状缓解。目前,通过为期2周的外周神经评估(PNE)来选择接受SNS治疗的患者,该评估包括使用临时电极进行刺激。然而,只有40%的测试反应者能从治疗中获得长期益处,这意味着每位成功治疗患者的医疗成本过高。主要目的是评估使用带倒刺电极测试来预测慢性便秘患者从SNS治疗中获益的情况。
采用随机双盲假对照交叉设计,使用带倒刺四极电极导线对增强型PNE(ePNE)进行为期6周的评估。该设计区分了对测试有辨别性反应和无辨别性反应的患者。在刺激期内,评分改善25%或更多被视为阳性反应。主要结局是在6个月时便秘症状评分至少降低0.5的患者比例。
共有45例患者被随机分组,其中29例(64.4%)在测试阶段有反应。其中27例接受了永久性SNS植入。在ePNE期间,7例(18%)为有辨别性反应者,22例(56%)为无辨别性反应者,10例(26%)为无反应者。6例患者在测试阶段因感染或不依从退出。在6个月时,有辨别性反应者和无辨别性反应者的主要结局无显著差异(60%对57%,P = 0.76)。由于在ePNE期间持续感染率为10例(22%),其中9例(20%)为严重感染,该研究提前终止。
ePNE对6个月时的治疗反应预测性较差。这表明在SNS的PNE和治疗过程中均存在强烈且持续的安慰剂反应。延长至6周的PNE会带来较高的感染风险。